Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Arlington Financial Advisors LLC

Arlington Financial Advisors LLC increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 1.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,694 shares of the medical research company’s stock after purchasing an additional 261 shares during the period. Amgen accounts for approximately 1.6% of Arlington Financial Advisors LLC’s portfolio, making the stock its 20th largest position. Arlington Financial Advisors LLC’s holdings in Amgen were worth $7,305,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of AMGN. BOK Financial Private Wealth Inc. purchased a new stake in Amgen in the fourth quarter valued at $29,000. United Community Bank purchased a new stake in Amgen in the fourth quarter valued at $29,000. Planned Solutions Inc. purchased a new stake in Amgen in the fourth quarter valued at $30,000. Delos Wealth Advisors LLC lifted its position in Amgen by 2,500.0% in the fourth quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 100 shares during the last quarter. Finally, Hartford Financial Management Inc. lifted its position in Amgen by 56.9% in the fourth quarter. Hartford Financial Management Inc. now owns 113 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 41 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

AMGN has been the subject of a number of research reports. TD Cowen reduced their target price on shares of Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a report on Wednesday, April 17th. BMO Capital Markets upped their target price on shares of Amgen from $336.00 to $355.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. William Blair raised shares of Amgen from a “market perform” rating to an “outperform” rating in a report on Friday, May 3rd. StockNews.com raised shares of Amgen from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. Finally, Royal Bank of Canada upped their target price on shares of Amgen from $328.00 to $332.00 and gave the company an “outperform” rating in a report on Friday, June 14th. Ten investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $307.35.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 2,117 shares of the stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $313.09, for a total value of $662,811.53. Following the sale, the senior vice president now directly owns 9,883 shares in the company, valued at $3,094,268.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.69% of the company’s stock.

Amgen Price Performance

AMGN traded down $1.24 on Friday, hitting $312.45. 3,518,174 shares of the company were exchanged, compared to its average volume of 2,437,626. The company has a debt-to-equity ratio of 11.96, a quick ratio of 0.98 and a current ratio of 1.42. The business’s fifty day moving average is $301.56 and its 200 day moving average is $292.30. Amgen Inc. has a fifty-two week low of $218.44 and a fifty-two week high of $329.72. The firm has a market capitalization of $167.61 billion, a P/E ratio of 44.64, a price-to-earnings-growth ratio of 2.82 and a beta of 0.60.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share for the quarter, topping the consensus estimate of $3.76 by $0.20. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The company had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.45 billion. During the same period in the prior year, the business posted $3.98 earnings per share. The firm’s revenue for the quarter was up 22.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Amgen Inc. will post 19.47 EPS for the current year.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.